Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GVO-1102,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenVivo Begins Patient Dosing in Phase I/Ib Trial for GEN2 Gene Vector Immunotherapy
Details : GEN2’s dose-escalation trial, GVO-1102 non-replicating immunotherapy vector administered by intravenous infusion with valganciclovir for the treatment of patients suffering from neoplasms.
Product Name : GVO-1102
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 27, 2024
Lead Product(s) : GVO-1102,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable